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ORIGINAL
STUDY

Journal of Acute Care Physical Therapy

Acute Physical and
Occupational Therapy and
Serum Potassium: When Is
It Safe?
Adele Myszenski, Nanette Hannum, Michael Hudson, Jerry Yee

ABSTRACT
Purpose: High or low serum potassium (K+) levels are associated with

increased risk of cardiac arrhythmias. No research-based guidelines or
suggested values for K+ in regard to safe provision of physical therapist
(PT) and occupational therapist (OT) services for patients in an acute
care setting are currently available. This study was designed to determine
whether patients with serum K+ levels of 3.1 to 5.9 mmol/L can participate
safely in acute PT and OT interventions without serious adverse events.

Methods: A total of 380 subjects admitted to an acute care hospital

were stratified into groups with hypokalemia (K+ levels of 3.1-3.4 mmol/L),
hyperkalemia (K+ levels of 5.1-5.9 mmol/L), or normal K+ levels (K+ levels
of 3.5-5.0 mmol/L) and provided with standard PT or OT intervention.
Baseline clinical characteristics and adverse outcomes were compared
between groups.

Results: No serious adverse events occurred. Termination of treatment

due to minor adverse events occurred in 8 (2%) subject cases and all
occurred in the normal K+ group (n = 8, 3%) (P = .029). Rates of adverse
outcomes did not differ significantly between normal (n = 37, 15.5%) and
abnormal K+ (n = 26, 16.4%) groups.

Conclusions: Results of this study suggest that provision of PT and OT

interventions for patients with serum K+ levels of 3.1 to 5.9 mmol/L is safe.
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S

erum potassium (K+) levels outside the standard
range of 3.5 to 5.0 mmol/L are associated with
increased risk of cardiac arrhythmias.1-6 Significant hypokalemia is associated with Q-T interval
prolongation and subsequent risk of ventricular fibrillation,7,8 while significant hyperkalemia is associated
with peaked T waves and widened QRS complexes
with subsequent risk for bradycardia and asystole.9,10
As such, both hypo- and hyperkalemic states can
put patients at risk for sudden cardiac death.11,12 Patients with acute illness are at risk for K+ imbalance
and cardiac arrhythmias.13-17 Mobility, activities of
daily living, and exercise are frequently initiated by
physical therapists (PTs) and occupational therapists
(OTs) during hospitalization.18,19 An exhaustive search
of recent literature via PubMed did not provide clear
guidelines or identify specific suggested values for
K+ in regard to safe provision of PT and OT service
and/or mobilization of patients in an acute care setting; however, the American Physical Therapy Association’s Academy of Acute Care provided a resource
suggesting a symptom-based approach for treating
patients with variable serum K+ levels.20,21 The current
standard of practice at Henry Ford Hospital allows for
provision of PT and OT interventions for patients with
K+ levels of 3.1 to 5.9 mmol/L and is based on expert
recommendations from the cardiology and nephrology departments within the institution and is included
in the rehabilitation department’s laboratory values
competency manual.22 No serious adverse events in
the treatment of these patients have been reported
in greater than 10 years. However, there is a lack of
compelling literature to demonstrate that PT and OT
interventions pose no significant threat to this patient
population. This study was designed to verify and validate our facility’s guidelines that patients with serum

K+ concentrations of 3.1 to 5.9 mmol/L can participate
safely in acute PT and OT interventions without serious adverse events to ensure that all eligible patients
receive rehabilitation (rehab) services when necessary
and appropriate and to provide evidence that is critically lacking in the literature.

METHODS
Data Collection
All patients admitted to Henry Ford Hospital with
serum K+ levels of 3.1 to 5.9 mmol/L were eligible for
inclusion in this study. Exclusion criteria omitted individuals with potassium levels of 3.0 mmol/L or less
and 6.0 mmol/L or greater, as well as individuals who
did not meet the specified guidelines for vital signs,
hemoglobin, platelets, blood glucose, and troponin
values outlined by the Henry Ford Hospital Rehab Services Lab Values Competency and Reference Manual
as listed in Table 1.21,22 Those eligible to participate in
the study were required to have heart rate and blood
pressure monitored pre-, mid-, and post-treatment and
documented in the daily therapy note.20-23 For the purposes of this project, abnormal K+ was subdivided into
2 groups: hypokalemia defined as K+ levels of 3.1 to 3.4
mmol/L, and hyperkalemia defined as K+ levels of 5.1
to 5.9 mmol/L. Normal K+ levels were defined as 3.5 to
5.0 mmol/L. Standard PT and OT services were defined
as “interventions designed to address patient-specific
impairments in musculoskeletal, neuromuscular, integumentary, cardiovascular, pulmonary, and/or cognitive
systems causing limitations in mobility or restrictions
in activities of daily living.” Treatment was terminated
with onset or increase in any symptoms outlined in
Table 1. Demographics collected included the following
comorbidities: coronary artery disease, end-stage renal

TABLE 1. Exclusion Criteria and Criteria for Termination of Treatment
Exclusion Criteria

Criteria for Termination of Treatment

Resting heart rate <50 or >120 beats per minute prior to
treatment
Systolic blood pressure <80 or >180 mm Hg prior to
treatment
Diastolic blood pressure <40 or >110 mm Hg prior to
treatment
Oxygen saturation levels ≤90% prior to treatment
Hemoglobin: ≤7.0 g/dL
Blood glucose <70 or >300 mg/dL
Troponin I: New-onset increase >0.2 ng/mL within 24 h
prior to treatment, or elevation between 0.05 and 0.2
within 24 h prior to treatment
JACPT ■ Volume 10 ■ Number 2 ■ 2019

Numbness or tingling in any body part
Dizziness not resolved/improved (as defined by the patient)
within 60 s of upright positioning
Nausea/vomiting
Blurred vision
Heart rate increase >30 beats per minute above resting
heart rate
Change in systolic blood pressure of ≥30 mm Hg or
change in diastolic blood pressure of ≤10 mm Hg
Anginal pain
Shortness of breath
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disease, chronic kidney disease, acute kidney injury,
atrial fibrillation, hypertension, congestive heart failure,
and chronic obstructive pulmonary disease. These were
chosen to reflect the comorbidities most commonly
associated with altered potassium levels and/or those
frequently associated with electrolyte imbalance. The
therapist also recorded the subject’s hospital unit (differentiated by patient population, intensive care unit, general practice unit, and telemetry). These demographics
and adverse outcomes were compared between subjects
with normal K+ levels and those with hypo- or hyperkalemia. This study was approved by the Henry Ford
Health System Institutional Review Board.

Data Analysis
All data were categorical and presented as count and
column percentages. Bivariate analyses were carried
out using a 2 × 2 χ2 or Fisher exact test if an expected
cell count was less than 5 and included K+ (normal/

abnormal) versus the presence of each comorbidity,
K+ (normal/abnormal) versus occurrence of each
adverse event, and K+ (normal/abnormal) versus need
for termination of treatment. Statistical significance
was set at P < .05. All analyses were performed using
SAS 9.4 (SAS Institute Inc, Cary, North Carolina).

RESULTS
A total of 380 subjects were enrolled in this study, including 68 subjects in intensive care units, 254 subjects in
general practice units, and 58 subjects in a cardiology
telemetry unit. The association between comorbidities
and K+ is provided in Table 2. Thirty-seven percent of
participants (n = 140) had abnormal K+ levels at the
time of PT or OT intervention. Sixty-three percent of
participants (n = 240) had normal K+ levels at the time
of PT or OT intervention. Hypokalemia was present in
97 (26%) patient cases and hyperkalemia was present

TABLE 2. Demographics
Normal K+ (n = 240)

Abnormal K+ (n = 140)

Pa

Coronary artery diseaseb

30 (13%)

20 (14%)

.619

End-stage renal diseaseb

0

8 (6%)

<.001

Chronic kidney diseaseb

32 (13%)

27 (19%)

.122

21 (9%)

20 (14%)

.093

33 (14%)

21 (15%)

.736

117 (49%)

85 (61%)

.024

Congestive heart failureb

28 (12%)

22 (16%)

.260

Chronic obstructive pulmonary
diseaseb

23 (10%)

15 (11%)

.723

Medical GPUc

44 (18%)

24 (17%)

N/A

Medical ICUc,d

9 (4%)

5 (4%)

N/A

Surgical GPUc

29 (12%)

15 (11%)

N/A

Surgical ICUc,d

39 (16%)

12 (9%)

N/A

Ortho GPUc

13 (5%)

11 (8%)

N/A

Neuro GPUc

48 (20%)

22 (16%)

N/A

Oncology GPUc

23 (10%)

13 (9%)

N/A

Cardiopulmonary GPUc,d

29 (12%)

29 (21%)

N/A

Cardiopulmonary ICUc,d

3 (1%)

0

N/A

Demographics (Count)

Acute kidney injuryb
Atrial fibrillationb
Hypertensionb

Abbreviations: GPU, general practice unit; ICU, intensive care unit; N/A, not applicable.
a
Values in boldface are statistically significant.
b
Comorbidity.
c
Hospital unit.
d
Telemetry monitoring available.
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in 43 (11%) patient cases. No serious adverse events
occurred in any study participant with normal or
abnormal K+ levels. Minor adverse events occurred in
48 subjects. As expected, no adverse events occurred
when highest level of mobility achieved was “nothing,” “sitting edge of bed,” or “marching in place.”
During interventions that included “transfer from bed
to chair,” 7 subjects experienced dyspnea and 1 subject experienced tachycardia. Two episodes of dyspnea
were reported in subjects who achieved “standing” but
not “marching in place.” Termination of intervention
due to minor adverse events occurred in 8 (2%) subject
cases. Significantly, all treatment sessions requiring
termination were in the normal K+ group (n = 8, 3%)

as compared with subjects with abnormal K+ (n = 0,
0%) (P = .029). Dyspnea was the only minor adverse
event significantly higher in the group with abnormal
K+ levels (n = 19, 14%) than in the group with normal
K+ levels (n = 16, 7%) (P = .028). End-stage renal
disease (P = .001) and hypertension (P = .024) were
comorbidities found significantly higher in the abnormal K+ group. An analysis of the differences in K+
levels between units was completed and reported in
Table 2; however, P values could not be determined
because the number of categories exceeded the limits
of the statistical analysis. Serious adverse events were
defined as “deaths or cardiopulmonary arrests requiring resuscitation during a PT or OT session.” Minor

TABLE 3. Adverse Events
Normal K+ (n = 240)

Abnormal K+ (n = 140)

Pa

Total subjects with adverse events

31 (13%)

23 (16%)

.344

Dyspneab

16 (6.6%)

19 (14%)

.028

Dizziness not resolved within 60 sec of
attaining upright positionb

6 (2.5%)

0

.089

Tachycardia/bradycardia (change of
≥30 bpm or needed intervention)b

5 (2.1%)

1 (1.0%)

.420

Desaturationb (<85% or intervention
required, ie, ↑ in Fio2)b

4 (1.6%)

4 (3.0%)

.473

Nausea/vomitingb

3 (1.3%)

0

.300

Hypotension (<10 mm Hg from rest
or needed intervention)b

2 (0.83%)

0

.533

Hypertension (>30 mm Hg from rest
or needed intervention)b

1 (0.42%)

1 (1.0%)

>.999

Anginab

0

1 (1.0%)

.368

New arrhythmia (excluding sinus
tachycardia and PVCs)b

0

0

N/A

Fall with or without staff assistance
in lowering patientb

0

0

N/A

New numbness or tingling in any body
partb

0

0

N/A

Blurred visionb

0

0

N/A

Cardiac arrest requiring CPRc

0

0

N/A

Deathc

0

0

N/A

8 (3.3%)

0

.029

Adverse Event (Count)

Required termination of treatment

Abbreviations: CPR, cardiopulmonary resuscitation; Fio2, fraction of inspired oxygen; N/A, not applicable; PVCs, premature ventricular
contractions.
a
Values in boldface are statistically significant.
b
Minor adverse event.
c
Serious adverse event.
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adverse events were defined as “undesirable, but nonlife threatening, physiologic signs or symptoms during a PT or OT session.” No serious adverse events
were recorded in any group. Fifty-four subjects were
reported to have at least 1 minor outcome (63 outcomes in total), but overall rates did not differ significantly between normal (n = 37, 15.5%) and abnormal
K+ (n = 26, 16.4%) groups. However, a greater rate
of PT or OT session termination due to minor adverse
events occurred in the normal K+ group than in the
groups with hyperkalemia (n = 12, 25.6%), hypokalemia (n = 14, 12.4%), and normokalemia (n = 37,
15.5%). Rates of adverse event by K+ strata are shown
in Table 3. Highest level of mobility achieved by K+
strata is shown in Table 4.

DISCUSSION
The results of this study support the safe initiation of
rehabilitation interventions for patients with serum
K+ levels of 3.1 to 5.9 mmol/L. No subjects included
in this study experienced any serious adverse events.
Rates of minor adverse events did not differ significantly between normal and abnormal K+ groups;
however, the specific cause for these events based on
the data collected could not be determined.

Literature supports the association between abnormal serum K+ levels and increased risk for cardiac
events.1,5,12,17 With increased myocardial demand
brought about by increased activity level, K+ concentrations should be a significant consideration for
PTs and OTs when making clinical decisions about
whether to initiate therapeutic intervention.18 As far as
we have found, this is the first study of its kind to investigate particular K+ levels at which initiation of PT and
OT services is safe. It was designed with the intention
that all patients who have potential to benefit from PT
and OT interventions receive appropriate treatments at
appropriate times. We were aware that telemetry monitoring is not routinely used for all patients in an acute
care setting with abnormal K+ levels who may be at risk
for developing arrhythmias. To address this concern,
the subjects were monitored for signs and symptoms
of arrhythmia (dizziness, dyspnea, blurred vision, significant change in heart rate or blood pressure, anginal
pain, paresthesia, and nausea/vomiting),18,20-22 and data
from these patients were included. Age, gender, and
acuity-level demographics were not collected for this
group of participants, and analysis of these statistics is
suggested for future research.
Individuals included in this study were noted to
have a wide variety of comorbidities, and the effect

TABLE 4. Highest Level of Mobility Achieved
Abnormal K+ (n = 140)
Normal K+
(N = 240)

Hypokalemia
(N = 97)

Hyperkalemia
(N = 43)

P

11 (4.6%)

0

2 (4.7%)

N/A

Sitting in bedb

5 (2.1%)

3 (3.1%)

1 (2.3%)

N/A

Sitting edge of bed <25% patient
initiationc

6 (2.5%)

3 (3.1%)

2 (4.7%)

N/A

Sitting edge of bed with some trunk
controld

12 (5.0%)

5 (5.2%)

4 (9.3%)

N/A

Standinge

16 (6.7%)

8 (8.2%)

4 (9.3%)

N/A

32 (13.3%)

17 (17.5%)

6 (14.0%)

N/A

3 (1.3%)

2 (2.1%)

1 (2.3%)

N/A

153 (63.8%)

58 (59.8%)

23 (53.5%)

N/A

Highest Level of Mobility
Nothinga

Transfer bed to chairf
Marching in placeg
Walkingh

Abbreviation: N/A, not applicable.
a
Passively rolled or exercised, splinted, raising head to upright.
b
Sitting in bed/exercise in bed, active rolling, bridging, exercises, supine to sit, cycle ergometer, tilt table.
c
Sitting edge of bed but with less than 25% initiation.
d
Sitting edge of bed, actively sitting over side of bed with some trunk control (may be assisted).
e
Standing: Weight-bearing through feet in standing position with or without assistance.
f
Transfer bed to chair with standing, able to step or shuffle, and transferring weight from one leg to another to move to chair.
g
Marching in place: Able to walk in place by lifting alternate feet at least 4 times with or without assistance.
h
Walking: Walking away from bed/chair by at least 4 steps (2 for each foot) assisted or gait aid or unassisted.
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and interaction between comorbidities in relation to
serum K+ levels could not be determined. Rates of
these minor adverse events did not appear to be related
to the difference between serum K+ concentrations in
this sample population. The effect of specific comorbidities on K+ levels is not well understood in relation
to activity and possible risk for developing potentially
dangerous arrhythmias. Specific levels of mobility for
patients with K+ in specific ranges have not been studied. Further research is needed to determine the most
appropriate guidelines for the provision of PT and OT
intervention for patients with specific diagnoses and at
differing exercise intensities in a population with varying K+ levels.

Limitations
Comprehensive patient demographics were not collected for this subject sample, which limits the ability
of the results of the study to be generalized. Telemetry
monitoring was not available for all subjects, which
required the researchers to rely on vital signs and symptoms for the detection of onset of new arrhythmia. Timing of blood draws and laboratory analysis of serum
potassium levels was not accounted for in relation to
potential electrolyte-balancing intervention (ie, intravenous administration of supplemental K+ or provision of sodium polystyrene sulfonate/Kayexalate) and
PT or OT intervention. It is possible that the low rate of
adverse events was confounded by the patient selection
criteria. As acute care clinicians are already aware, the
practicality of providing intervention only for patients
who would meet the exclusion criteria for this study is
not always realistic. This may warrant investigation of
the safety of PT and OT intervention for patients with
abnormal K+ and stable hypo-/hypertension, and/or
tachy-/bradycardia in future research.

CONCLUSION
This study suggests that PT and OT intervention in
patients with serum K+ levels of 3.1 to 5.9 mmol/L is
safe. Subjects in an acute care setting, with and without telemetry monitoring, participated in therapeutic
activities without any serious adverse events. Patients
with K+ levels of 3.1 to 5.9 mmol/L should not be
excluded from receiving PT or OT services based
solely on concern for cardiac arrhythmias related to
this laboratory value.
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